Court Report - August 26, 2012

[author: Sherri Oslick]

Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Merck Sharp & Dohme Corp. v. Watson Laboratories, Inc.
3:12-cv-05228; filed August 20, 2012 in the District Court of New Jersey

Infringement of U.S. Patent Nos. 5,571,817 ("Methods of Treating Androgenic Alopecia with Finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]," issued November 5, 1996), 5,547,957 ("Method of Treating Androgenic Alopecia with 5-α Reductase Inhibitors," issued August 20, 1996), and 5,886,184 ("Finasteride Processes," issued March 23, 1999) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Merck's Propecia® (finasteride, used to treat androgenic alopecia).  View the complaint here.  [NB: Merck voluntarily dismissed the case without prejudice 3 days after filing.]

Santarus, Inc. et al. v. Dr. Reddy's Laboratories Inc. et al.
3:12-cv-05202; filed August 15, 2012 in the District Court of New Jersey

• Plaintiffs:  Santarus, Inc.; The Curators of The University of Missouri
• Defendants:  Dr. Reddy's Laboratories Inc.; Dr. Reddy's Laboratories, Ltd.

Infringement of U.S. Patent Nos. 6,699,885 ("Substituted Benzimidazole Dosage Forms and Methods of Using Same," issued March 2, 2004), 6,489,346 (same title, issued December 3, 2002), 6,645,988 (same title, issue November 11, 2003), and 7,399,772 (same title, issued July 15, 2008) following a Paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of Santarus' Zegerid® (omeprazole/sodium bicarbonate, used to treat heartburn and other symptoms associated with gastroesophageal reflux disease).  View the complaint here.

 

Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.
×
Loading...
×